{
    "clinical_study": {
        "@rank": "13310", 
        "arm_group": [
            {
                "arm_group_label": "CLP 15 g Fed", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack"
            }, 
            {
                "arm_group_label": "CLP 25 g Fed", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack"
            }, 
            {
                "arm_group_label": "CLP 7.5 g Fed", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack"
            }, 
            {
                "arm_group_label": "CLP 15 g fasted", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a dose-escalation study to determine the effect of CLP in normal healthy volunteers."
        }, 
        "brief_title": "Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers", 
        "condition": "Basic Science: Safety, Tolerability, Efficacy of CLP", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or females between the ages of 18 and 70 years\n\n          -  Body mass index (BMI) between 18 and 32 kg/m^2, inclusive\n\n          -  Females could not be pregnant or breast feeding and had to be using birth control\n\n        Exclusion Criteria:\n\n          -  Positive drug screen for substances of abuse\n\n          -  Positive results for HIV, hepatitis B, or hepatitis C\n\n          -  Screening 12-lead ECG demonstrating QTc interval >430 msec for males and >450 msec\n             for females, or any cardiac rhythm disorder considered by the Investigator to be\n             clinically relevant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944007", 
            "org_study_id": "CTST-5"
        }, 
        "intervention": {
            "arm_group_label": [
                "CLP 15 g Fed", 
                "CLP 25 g Fed", 
                "CLP 7.5 g Fed", 
                "CLP 15 g fasted"
            ], 
            "description": "CLP was administered orally, in capsules, for 9 consecutive days.", 
            "intervention_name": "Cross-Linked Polyelectrolyte (CLP)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "CLP", 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan"
                }, 
                "name": "Jasper Clinic, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open-label Phase 1 Multiple Dose Escalation Trial to Assess the Safety, Tolerability, and Efficacy of Capsules Containing Cross-linked Polyelectrolyte (CLP) Given to Normal Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Jasper Clinic, Inc.", 
            "last_name": "Thomas Blok, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Daily net sodium balance was calculated based on dietary and fluid intake, urinary and fecal output and emesis.", 
            "measure": "Net Sodium Balance", 
            "safety_issue": "No", 
            "time_frame": "Days 5 - 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total fecal weight throughout 9-day treatment period, and mean fecal weights (daily avg. of Days 5-9)", 
                "measure": "Total Fecal Weight", 
                "safety_issue": "No", 
                "time_frame": "Days 1-9"
            }, 
            {
                "description": "The net balance of cations was calculated based on dietary and fluid intake, urinary and fecal output, and emesis.", 
                "measure": "Net Balance of Potassium, Magnesium, Calcium, and Phosphorous", 
                "safety_issue": "No", 
                "time_frame": "Days 5-9"
            }, 
            {
                "measure": "Fecal content and concentration of sodium, potassium, magnesium, calcium, phosphorous, iron, zinc, and copper", 
                "safety_issue": "No", 
                "time_frame": "Days 5-9"
            }, 
            {
                "measure": "Urine content and concentration of sodium, potassium, magnesium, calcium, and phosphorous", 
                "safety_issue": "No", 
                "time_frame": "Days 5-9"
            }, 
            {
                "measure": "Serum concentrations of sodium, potassium, magnesium, calcium, and phosphorous", 
                "safety_issue": "Yes", 
                "time_frame": "Days 5-9"
            }
        ], 
        "source": "Sorbent Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sorbent Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}